- Benzinga•12 hours ago
JMP Securities’ Michael G. King, Jr. believes there is limited near-term upside for Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ), given the prescription trends and the ongoing scrutiny of Iclusig's pricing. ...
- Investor's Business Daily•yesterday
Ariad was feeling some Mylan-like pressure Monday on Congress' looming deadline to submit information about a drug price hike.
Ariad Pharmaceuticals Inc. (ARIA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||9.34 x 500|
|Ask||9.85 x 100|
|Day's Range||9.12 - 9.57|
|52wk Range||4.37 - 14.34|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-29.94|
|Avg Vol (3m)||6,737,200|
|Dividend & Yield||N/A (N/A)|